How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

23,877 results for

Quality Adjusted Life Year

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Quality of life and quality-adjusted life years of chronic schistosomiasis mansoni patients in Brazil in 2015. (PubMed)

Quality of life and quality-adjusted life years of chronic schistosomiasis mansoni patients in Brazil in 2015. Measures of health-related quality of life (HRQoL) have been used to express the impact of neglected diseases and to generate indicators for health economic assessments. Schistosomiasis mansoni is a neglected disease with various clinical manifestations, including severe repercussions, caused by parasitic worms. Here we describe the quality of life of chronic schistosomiasis mansoni (...) patients and estimate the quality-adjusted life years (QALYs) associated with chronic schistosomiasis mansoni in Brazil in 2015.A HRQoL study was carried out using the three-level European Quality of Life 5-Dimensions (EQ-5D-3L) questionnaire in 147 chronic schistosomiasis mansoni patients at an outpatient monitoring facility of an endemic state for schistosomiasis.Losses in HRQoL were observed in all five dimensions of the EQ-5D-3L. Patients >60 y and 40-49 y of age reported the highest frequencies

Full Text available with Trip Pro

2018 Transactions of the Royal Society of Tropical Medicine & Hygiene

2. Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity (PubMed)

Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity Contingent valuation is widely used to determine individuals' willingness to pay (WTP) for a health gain. Our study aimed to elicit an empirical estimate of the monetary value of a quality-adjusted life year (QALY) in a Greek outpatient setting in times of economic austerity and assess the impact of patients' characteristics on their valuations.We used a questionnaire (...) as a survey tool to determine the maximum WTP for a health gain of a hypothetical therapy and to evaluate patients' health-related quality of life (EuroQoL-5D-3L) and demographic and socioeconomic characteristics. EuroQoL tariffs were used to estimate health utilities. Mean WTP values were computed and ordinary least squares regressions performed on transformed Box-Cox and logarithmic dependent WTP per QALY variables to remedy observed skewness problems.Analyses were performed for 167 patients

Full Text available with Trip Pro

2017 PharmacoEconomics open

3. Quality-adjusted life years in Alzheimer's Disease: a systematic review

Quality-adjusted life years in Alzheimer's Disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (...) outcome(s) Example: 1st author, year of publication, language, journal. ">Data to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis is not possible, data will be reported through a descriptive summary. ">Planned approach If a meta-analysis is planned , please specify

2019 PROSPERO

4. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year with emphasis on estimation procedures

A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year with emphasis on estimation procedures Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) by Jablonski scale; continuous; Jablonski score. ">Data to be extracted: secondary outcome(s) Example: 1st author, year of publication, language, journal. ">Data to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis is not possible, data will be reported through a descriptive summary

2019 PROSPERO

5. An economic evaluation of a telephone outcall intervention for informal carers of cancer patients in Australia: An assessment of costs and quality-adjusted-life-years. (PubMed)

An economic evaluation of a telephone outcall intervention for informal carers of cancer patients in Australia: An assessment of costs and quality-adjusted-life-years. Carers of people with cancer provide uncompensated care that is often physically, emotionally, and financially demanding, which results in neglect of their own health. This study's objective was to conduct an economic evaluation following a randomised control trial (RCT) involving a proactive telephone outcall intervention aimed (...) was reduced carer burden. Health care resource use was measured using a resource use questionnaire (RUQ), and costs were presented in 2013 $(AUS). Quality-adjusted-life-years (QALYs) were also used as health outcomes. An incremental cost-effectiveness ratio (ICER) was calculated, with bootstrapping used to quantify sampling variability. A $50 000 per QALY-gained willingness-to-pay threshold was used. Sensitivity analyses were conducted.Results showed that the total mean QALYs-gained were higher (0.02

2019 Psycho-oncology

6. Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare. (PubMed)

Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare. Healthcare expenditures in the United States continue to grow; to control costs, there has been a shift away from volume-focused care to value-based care. The incorporation of patient perspectives in the development of value-based healthcare is critical, yet research addressing this issue is limited. This study explores awareness and understanding of patients with cancer about the quality (...) -adjusted life year (QALY), as well as their perspectives regarding the use of the QALY to measure value in healthcare.This cross-sectional study used survey methodology to explore patient awareness, understanding, and perspectives on the QALY. A total of 774 patients with cancer and survivors completed this survey in June and July of 2017. Quantitative and qualitative analyses were conducted.Results showed that there is limited awareness of the QALY among patients with cancer and survivors and minimal

2019 Value in Health

7. Total Hip Arthroplasty Improves the Quality-Adjusted Life Years in Patients Who Exceeded the Estimated Life Expectancy. (PubMed)

Total Hip Arthroplasty Improves the Quality-Adjusted Life Years in Patients Who Exceeded the Estimated Life Expectancy. Hip osteoarthritis is a leading cause of functional decline and disability in the elderly. Although patients older than 80 years could significantly benefit from an elective total hip arthroplasty (THA), they pose a significant challenge to both anesthesiologist and arthroplasty surgeon. The purpose of this study was to report the clinical outcomes, complication rate (...) , mortality, and quality-adjusted life year (QALY) of THA in patients who already exceeded the average life expectancy.Patients treated with elective THA for debilitating hip osteoarthritis and already exceeded the average life expectancy in Switzerland (n = 100) were included. The complication rate, QALY, and 30-day, 1-year, and midterm mortality were assessed retrospectively.The overall complication rate was 12%. The 30-day and 1-year mortality was 3% and 6%, respectively. The Harris hip score increased

2018 Journal of Arthroplasty

8. Quantifying life: Understanding the history of Quality-Adjusted Life-Years (QALYs). (PubMed)

Quantifying life: Understanding the history of Quality-Adjusted Life-Years (QALYs). Quality-Adjusted Life-Years (QALYs) are central to healthcare decision-making in Britain and abroad, yet their history is poorly understood. In this paper, we argue that a more in-depth and political history of the QALY is needed to allow a critical evaluation of its current dominance. Exploiting rich data from archives and 44 semi-structured interviews conducted between 2015 and 2018, we employ Multiple Streams

Full Text available with Trip Pro

2018 Social Science & Medicine

9. A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data. (PubMed)

A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data. To use real-world data to develop a flexible generic decision model to predict cost, life expectancy, and quality-adjusted life-years (QALYs) for follicular lymphoma (FL) in the general patient population.All patients newly diagnosed with FL in the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) between 2004 (...) compared to current practice.Incidence-based analysis revealed expected average lifetime costs ranging from £6,165 [US$7,709] to £63,864 [US$79,862] per patient, and average life expectancy from 75 days to 17.56 years. Prevalence-based analysis estimated average annual treatment costs of £60-65 million [US$75-80 million], accounting for approximately 10% of the United Kingdom's annual National Health Service budget for hematological cancers as a whole. Assuming that treatment effects reported in trials

Full Text available with Trip Pro

2018 Value in Health

10. New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment? (PubMed)

New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment? 28717746 2019 01 13 2378-9506 3 1 2017 Feb Journal of global oncology J Glob Oncol New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment? 82-83 10.1200/JGO.2016.006361 Messori Andrea A ESTAR, Regional Health Service, Firenze, Italy. eng Journal Article 2016 08 10 United States J Glob Oncol 101674751

Full Text available with Trip Pro

2016 Journal of global oncology

11. Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. (PubMed)

Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. This study evaluated the utility and quality-of-life year measurements for patients with coronary artery disease who underwent any of 3 therapeutic strategies with a 5-year follow-up.Quality-of-life data were obtained from the Medicine, Angioplasty, or Surgery Study II trial. To obtain utilities, the 36-Item Short-Form questionnaire was converted to a 6-Dimensional Health State (...) percutaneous coronary intervention and medical treatment was statistically significant (P < .05, Dunn test). The median cumulative quality-of-life years across the 5 years were 3.802 (95% CI 3.668-3.936) for percutaneous, 3.540 (95% CI 3.399-3.681) for medical, and 3.764 (95% CI 3.638-3.890) for surgery. Additionally, the median quality-of-life years between percutaneous and medical treatment was 0.262 (95% CI 0.068-0.456), between surgery and medical treatment it was 0.224 (95% CI 0.036-0.413

Full Text available with Trip Pro

2017 Medicine

12. Incremental decreases in quality-adjusted life years (QALY) associated with higher levels of depressive symptoms for U.S. Adults aged 65 years and older (PubMed)

Incremental decreases in quality-adjusted life years (QALY) associated with higher levels of depressive symptoms for U.S. Adults aged 65 years and older Quality-adjusted life years (QALY) is a single value index that quantifies the overall burden of disease. It reflects all aspects of heath, including nonfatal illness and mortality outcomes by weighting life-years lived with health-related quality of life (HRQOL) scores. This study examine the burden of disease due to increasing levels (...) of depressive symptoms by examining the association between the 9-item Patient Health Questionnaire (PHQ-9) scores and QALY for U.S. adults aged 65 years and older.We ascertained respondents' HRQOL scores and mortality status from the 2005-2006, 2007-2008, and 2009-2010 cohorts of the National Health and Nutrition Examination Survey (NHANES) with mortality follow-up data through December 31, 2011. This analysis included respondents aged 65 years and older (n = 3,680). We estimated the mean QALY throughout

Full Text available with Trip Pro

2017 Health and quality of life outcomes

13. Disparities in total knee replacement: Population losses in quality-adjusted life years due to differential offer, acceptance, and complication rates for Black Americans. (PubMed)

Disparities in total knee replacement: Population losses in quality-adjusted life years due to differential offer, acceptance, and complication rates for Black Americans. Total knee replacement (TKR) is an effective treatment for end-stage knee osteoarthritis (OA). American racial minorities undergo fewer TKRs than whites. We estimated quality-adjusted life-years (QALYs) lost for African American knee OA patients due to differences in TKR offer, acceptance, and complication rates.We used

2018 Arthritis care & research

14. Quality-adjusted Life Years (QALY) for 15 Chronic Conditions and Combinations of Conditions Among US Adults Aged 65 and Older. (PubMed)

Quality-adjusted Life Years (QALY) for 15 Chronic Conditions and Combinations of Conditions Among US Adults Aged 65 and Older. Although the life expectancy for the US population has increased, a high proportion of this population has lived with ≥1 chronic conditions. We have quantified the burden of disease associated with 15 chronic conditions and combinations of conditions by estimating quality-adjusted life years (QALYs) for older US adults.Data were from the Medicare Health Outcomes Survey (...) Cohort 15 (baseline survey in 2012, follow-up survey 2014, with mortality follow-up through January 31, 2015). We included individuals aged 65 years and older (n=96,481). We estimated mean QALY throughout the remainder of the lifetime according to the occurrence of these conditions.The age-adjusted QALY was 5.8 years for men and 7.8 years for women. Over 90% respondents reported at least 1 condition and 72% reported multiple conditions. Respondents with depression and congestive heart failure had

2018 Medical Care

15. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey. (PubMed)

Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey. Cost-effectiveness is 1 of the most important factors in medicine reimbursement, and social willingness to pay (WTP) can provide evidence for the threshold of cost-effectiveness analysis. Recently, the concept of curative medicines has been introduced, so it is necessary to study their cost-effectiveness. This study aimed to estimate WTP per quality-adjusted (...) life year (QALY) for a cure in the Korean general population.A total of 507 people from the general population, proportionally assigned by sex, age, and region, participated in face-to-face interviews. The contingent valuation survey was conducted with scenarios involving 4 EuroQol-5 dimensions (EQ-5D) with different health statuses. We assumed a treatment that moved the health status of each scenario to perfect health. WTP for 1 year of treatment was derived using a double-bounded format followed

Full Text available with Trip Pro

2018 Medicine

16. Quality-Adjusted Life-Years without Constant Proportionality. (PubMed)

Quality-Adjusted Life-Years without Constant Proportionality. A quality-adjusted life-year is a common unit of measurement in health valuation. Under its constant proportionality assumption, the value of a quality-adjusted life span is defined as the product of preference weight and life span.To empirically identify an alternative functional relationship between life span and value by relaxing the constant proportionality assumption.Using an online survey, 5367 respondents completed 30 to 40 (...) and value on a quality-adjusted life-year scale.The results reject constant proportionality (P < 0.01) and support the use of a power function to describe the relationship between life span and value, namely, value = preference weight × life spanβ. The estimate of power (β = 0.415; 95% confidence interval 0.41-0.42) appears to depend on whether life span was expressed in a temporal unit of days (0.403), weeks (0.509), months (0.541), or years (0.654).Raising life span to a power less than 1 implies

2018 Value in Health

17. Quality-Adjusted Life Years Gained by Hip and Knee Replacement Surgery and Its Aftercare. (PubMed)

Quality-Adjusted Life Years Gained by Hip and Knee Replacement Surgery and Its Aftercare. To determine the lifetime quality-adjusted life years (QALYs) gained by total joint arthroplasty (TJA), and assess the QALYs attributed to specific postoperative rehabilitation interventions.Secondary analysis of 2 multicenter, randomized controlled trials (RCTs) with 3-, 6-, 12-, and 24-month follow-up.Two university hospitals, 2 municipal hospitals, and 1 rural hospital.Patients (N=827) who underwent (...) arthroplasty, the lifetime QALYs increased by 2.35 years in the nonergometer group, and by 2.30 years in the early aquatic therapy group. However, after knee arthroplasty, the lifetime QALYs increased by 1.81 years in the nonergometer group, and by 1.60 years in the early aquatic therapy group. By ergometer cycling, .55 additional QALYs could be gained after hip and .10 additional QALYs after knee arthroplasty, while the additional QALYs attributed to the timing of aquatic therapy were .12 years after hip

2017 Archives of physical medicine and rehabilitation

18. Results and methodology of cost-utility evaluation of cataract surgery in developed countries: Quality-adjusted life years and cataract. (PubMed)

Results and methodology of cost-utility evaluation of cataract surgery in developed countries: Quality-adjusted life years and cataract. This review surveyed the results and methods of cost-utility analyses of cataract surgery. Thirteen studies were included. Based on decision-theoretic time trade-off, utilities ranged from 0.148 to 0.8 and quality-adjusted life years (QALY) ranged from 1.424 to 2.43. Based on psychometric instruments such as Euroqol 5 dimensions, utilities ranged from 0.017

2017 Journal of cataract and refractive surgery

19. The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review. (PubMed)

The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review. In cost-effectiveness analyses in healthcare, Quality-Adjusted Life Years are often used as outcome measure of effectiveness. However, there is an ongoing debate concerning the appropriateness of its use for decision-making in palliative care.To systematically map pros and cons of using the Quality-Adjusted Life Year to inform decisions on resource (...) allocation among palliative care interventions, as brought forward in the debate, and to discuss the Quality-Adjusted Life Year's value for palliative care.The integrative review method of Whittemore and Knafl was followed. Theoretical arguments and empirical findings were mapped.A literature search was conducted in PubMed, EMBASE, and CINAHL, in which MeSH (Medical Subject Headings) terms were Palliative Care, Cost-Benefit Analysis, Quality of Life, and Quality-Adjusted Life Years.Three themes regarding

Full Text available with Trip Pro

2017 Palliative medicine

20. OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients? (PubMed)

OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients? To understand the limitations with current patient-reported outcome measures (PROM) used to generate quality-adjusted life-years (QALY) in rheumatology, and set a research agenda.Two activities were undertaken. The first was a scoping review of published studies that have used PROM to generate QALY in rheumatology between 2011 and 2016. The second was an interactive "eyeball test

2017 Journal of Rheumatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>